JLE

Innovations & Thérapeutiques en Oncologie

MENU

A best in class TLR3 agonist soon to be clinically available. TL-532 as new therapeutic approach in immuno-oncology Volume 7, issue 1, January-February 2021

Figures


  • Figure 1

  • Figure 2

  • Figure 3

  • Figure 4
Author
Cofondateur de la société Tollys
Responsable du business développement
41, quai Fulchiron
69005 Lyon
France
* Tirés à part

Tollys is a biopharmaceutical company focused on innate immunity, particularly on the biology and modulation of the toll-like receptor, TLR3. It is pioneering TL-532 as a new immunotherapy to treat various types of cancers.

The company has discovered and patented a family of TLR3 agonists and has selected TL-532 as its leading candidate, as it is highly specific to the TLR3 receptor. Preclinical testing is currently underway, with very promising results in vitro, in vivo and ex vivo.

The company, situated in Lyon, France, was founded in 2015 together with scientists from from Centre de recherche en cancérologie de Lyon and the Centre Léon-Bérard.